目的：比较适利达与类似药物Drenatan在原发性开角型青光眼患者中关于降低眼内压的单药治疗疗效。

方法：该回顾性研究包括62例患者(119眼)。初诊时，正在使用适利达的患者转为使用类似药物拉坦前列素(Drenatan)。12wk后的复诊阶段进行全面的眼科检查，包括裂隙灯、Goldmann压平眼压计、立体眼底、前房角镜、超声角膜测厚仪以及自动视野检查。

结果：使用Drenatan之前和之后平均眼内压分别为12.30±2.02mmHg和12.38±2.05mmHg(P=0.559)。R=0.987显示两者显著相关。

结论：适利达和Drenatan在降低眼内压方面具有相似功效。该发现对于降低公共卫生成本，维护其药物疗效和安全性政策具有重要意义。

METHODS: Sixty two patients(119 eyes)were enrolled in this observational, retrospective study. In the first visit, the patient came in using the brand latanoprost(Xalatan)and it was changed to the similar latanoprost(Drenatan). In the second visit, 12wk later, a complete ophtalmologic exam including slit lamp examination, Goldmann applanation tonometry, stereoscopic fundus examination, gonioscopy, ultrasound pachymetry, automated visual field testing was performed.

RESULTS:The mean IOP was 12.30±2.02mmHg and 12.38±2.05mmHg with using Xalatan and Drenatan, respectively. The P=0.559 demonstrates this relation. In fact, a correlation between the groups of R=0.987 points out the remarkable resemblance of both groups.

CONCLUSION: Both Drenatan and Xalatan have similar efficacy in reducing IOP. Such finding is pivotal to public health to reduce cost and maintain its policies concerning drug efficacy and safety, this is especially significant in countries in which treatment cost is a barrier for patient adhesion to treatment.